Keyphrases
ChAdOx1
100%
BNT162b2
100%
Immunogenicity
62%
Reactogenicity
62%
Second Dose
54%
Research Ethics Committees
50%
Phase II Trial
50%
Clinical Trials
50%
Receptor-binding Domain
50%
Immunogenic
50%
BNT162b2 Vaccine
50%
SARS-CoV-2 Variants
50%
Domain Antibody
45%
Immunoassay
41%
Day 14
29%
Trimeric Spike Protein
25%
Intervention Group
25%
Omicron Variant
25%
Beta Variant
25%
Spain
20%
Virus Neutralization
20%
Interferon-α (IFN-α)
20%
Geometric Mean Titer
20%
EudraCT
20%
Immune Response
20%
Antibody Functionality
20%
Cellular Immune Response
20%
Commercial Trial
20%
COVID-19
16%
Salud
12%
Detrimental Effects
12%
Delta Variant
12%
Revaccination
12%
SARS-CoV-2 Receptor Binding Domain
12%
Antibody Decay
12%
Alpha Variant
12%
G614
12%
Humoral Immunogenicity
12%
Cellular Response
12%
Humoral Response
12%
Interleukin-2
12%
Titre
12%
Vaccination
12%
Laboratory Data
12%
Drug Evaluation
10%
Design Characteristics
10%
Pharmaceutical Industry
10%
Retrospective Observational Study
10%
Non-commercial Trials
10%
Clinical Research
10%
Medicine and Dentistry
Receptor Binding
87%
Immunogenicity
83%
Severe Acute Respiratory Syndrome Coronavirus 2
75%
Reactogenicity
66%
Neutralization
62%
Immunoassay
58%
Clinical Trial
50%
Retrospective Study
50%
Adverse Event
37%
Omicron Coronavirus Variant
33%
Immune Response
29%
Cellular Immunity
29%
Interferon
29%
Vaccine
16%
Interleukin 2
16%
Infection
12%
Injection Site Pain
12%
Intramuscular Injection
12%
Single Drug Dose
12%
Headache
12%
Myalgia
12%
Randomized Controlled Trial
12%
COVID-19
12%
Protein Tertiary Structure
12%
Clinical Research
10%
Drug Screening
10%
Observational Study
10%
Immunology and Microbiology
Receptor Binding
100%
Immunology
83%
Immunogenicity
83%
Severe Acute Respiratory Syndrome Coronavirus 2
83%
Immunoassay
66%
Neutralization
66%
Spike
50%
Dynamics
50%
Omicron Coronavirus Variant
33%
Adoptive Immunity
33%
Interferon Type I
33%
Immune Response
33%
Protein Binding
16%
Vaccination Schedule
16%
Vaccine
16%
Interleukin 2
16%
COVID-19
16%
Vaccine Efficacy
16%
Protein Tertiary Structure
16%